Avidity Biosciences (RNA) Payables: 2019-2025
Historic Payables for Avidity Biosciences (RNA) over the last 6 years, with Sep 2025 value amounting to $9.6 million.
- Avidity Biosciences' Payables fell 80.60% to $9.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $76.2 million, marking a year-over-year decrease of 53.03%. This contributed to the annual value of $8.5 million for FY2024, which is 75.36% down from last year.
- As of Q3 2025, Avidity Biosciences' Payables stood at $9.6 million, which was up 145.94% from $3.9 million recorded in Q2 2025.
- In the past 5 years, Avidity Biosciences' Payables ranged from a high of $54.2 million in Q1 2025 and a low of $3.9 million during Q2 2025.
- Moreover, its 3-year median value for Payables was $33.9 million (2023), whereas its average is $30.5 million.
- Per our database at Business Quant, Avidity Biosciences' Payables surged by 140.71% in 2022 and then plummeted by 90.44% in 2025.
- Quarterly analysis of 5 years shows Avidity Biosciences' Payables stood at $14.1 million in 2021, then skyrocketed by 131.25% to $32.6 million in 2022, then rose by 5.43% to $34.3 million in 2023, then tumbled by 75.36% to $8.5 million in 2024, then tumbled by 80.60% to $9.6 million in 2025.
- Its Payables was $9.6 million in Q3 2025, compared to $3.9 million in Q2 2025 and $54.2 million in Q1 2025.